RaQualia Pharma Inc. risk profile
58 Elevated one input has moved against it
Measured 23 October 2026 from 4579.T's filed statements. Recomputed nightly.
58 (Elevated), driven by Cash conversion at 100, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 83 | Acute | Volatile | One-year price volatility — 76.7% |
| Operating pressure | 45 | Elevated | Stable | Operating-margin drift — -17.5 percentage points |
| Cash conversion | 100 | Acute | Worsening | Capital spending against operating cash — -0.21x |
| Leverage and coverage | 4 | Contained | Easing | Interest cover — 16.68x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for RaQualia Pharma Inc.